Our Company

ALNYLAM IS LEADING THE RNAi REVOLUTION™

Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them.

Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, four more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases.

What’s in a Name?

AL-NY-LAM. Our name may not be the easiest to pronounce, but once you learn it, you’ll never forget it.

Alnylam is derived from “Alnilam,” the bright center star in the constellation Orion’s belt, which has been used by navigators for thousands of years and symbolizes our passion for discovery.

The Leader in RNAi Therapeutics

Medicines based on RNAi work by “silencing” or disabling the production (“expression”) of the genes that cause specific diseases. Since our medicines work at a genetic level, we believe that we can develop small interfering RNAs that can silence virtually any gene in the genome, meaning that the diseases we’re treating with RNAi therapeutics today, are just the beginning of what’s possible.

Leading by Example

Corporate Responsibility

We accept bold challenges to improve the health of humanity. We believe that our actions as a company and employees can be a force for good in the world.

LEARN MORE ›